| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Budesonide systemic preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clobetasol propionate topical preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clobetasone butyrate topical preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing desonide in topical dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Diflorasone diacetate topical preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing desoximetasone in topical dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Diflucortolone valerate topical preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fluocinolone acetonide topical preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fluocortolone topical preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Flurandrenolide topical preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fluticasone propionate topical preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Halcinonide topical preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone acetate topical preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Mometasone furoate topical preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone acetonide topical preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rimexolone ophthalmic preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Loteprednol etabonate ophthalmic preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desoxycorticosterone acetate systemic preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone 500micrograms soluble tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone 500 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| bétaméthasone 4 mg/mL, ampoule de 1 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely cortisone acetate 25 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone 500 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone 100 microgram/mL oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone 2mg/5mL s/f oral solution (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phosphate 10mg/2mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone 2mg/5mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone phosphate 120mg/5mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone phosphate 8mg/2mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone phosphate 4mg/1mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone 10 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely hydrocortisone 20 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely hydrocortisone 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone 500mg/5mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone 100mg/1mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone 100mg powder and solvent for injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone acetate+lignocaine hydrochloride 80/20mg/2mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| acétate de méthylprednisolone et chlorhydrate de lidocaïne 40/10 mg/1 mL pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| acétate de méthylprednisolone 40mg/mL, fiole de 3 mL de suspension injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| méthylprednisolone 50 mg/mL, flacon de 10 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone 1g/20mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone 500mg injection (pdr for recon) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| méthylprednisolone 1 g, fiole de poudre pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone 4 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone 16 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| méthylprednisolone 40 mg, fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| méthylprednisolone 125 mg, fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| méthylprednisolone 500 mg, fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| méthylprednisolone 1 g, fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| méthylprednisolone 2 g, fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone acetate 40mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone acetate 80mg/2mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone 2.5 mg gastro-resistant oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely prednisolone 5 milligram/1 each gastro-resistant oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone 5mg soluble tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely prednisolone 25 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisone 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| acétonide de triamcinolone 40 mg/mL, seringue préremplie de 2 mL de suspension injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone acetonide 40mg/1mL i-m prefilled syringe (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Deflazacort 6 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely deflazacort 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Deflazacort 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phosphate 5mg/1mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 25mg/1mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate 25mg/1mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone acetonide 10mg/1mL intra-articular/intradermal injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone acetonide 50mg/5mL intra-articular/intradermal injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone acetonide 40mg/1mL intra-articular/intramuscular inj |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone hexacetonide 25mg/5mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone sodium phosphate+neomycin sulfate 0.1/0.5% eye ointment (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone sodium phosphate 1 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clobetasone butyrate 1 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phosphate 0.1% single-use eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone+hypromellose 0.1%/0.5% eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fluorometholone 1 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 5 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely hydrocortisone acetate 10 milligram/1 gram conventional release eye ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 2.5% eye ointment (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 1% eye drops (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone sodium phosphate 0.5% single-use eye drops (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely rimexolone 10 milligram/1 milliliter conventional release eye drops (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clioquinol 10 mg/mL and flumetasone pivalate 200 microgram/mL ear drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely gentamicin (as gentamicin sulfate) 3 milligram/1 milliliter and hydrocortisone acetate 10 milligram/1 milliliter conventional release ear drops (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Neomycin+hydrocortisone 0.5%/1.5% ear drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely neomycin sulfate 5 milligram/1 milliliter and prednisolone sodium phosphate 5 milligram/1 milliliter conventional release solution for ear or eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely hydrocortisone acetate 15 milligram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release ear and eye ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely hydrocortisone acetate 15 milligram/1 milliliter and neomycin sulfate 5 milligram/1 milliliter conventional release solution for ear or eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone (as betamethasone sodium phosphate) 1 mg/mL and neomycin sulfate 5 mg/mL ear and eye and nose drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely neomycin 3.5 milligram/1 milliliter and triamcinolone acetonide 1 milligram/1 milliliter conventional release ear drops (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Beclomethasone dipropionate 50micrograms aqueous nasal spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Budesonide 100micrograms aqueous nasal spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fluticasone propionate 50micrograms aqueous nasal spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fluticasone propionate 400micrograms single-use nasal drops (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone acetonide 55microgram aqueous nasal spray (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Tramazoline hydrochloride+dexamethasone isonicotinate (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]